| Title |
Statin use and risk of glioma: population-based case–control analysis
|
|---|---|
| Published in |
European Journal of Epidemiology, April 2016
|
| DOI | 10.1007/s10654-016-0145-7 |
| Pubmed ID | |
| Authors |
Corinna Seliger, Christoph Rudolf Meier, Claudia Becker, Susan Sara Jick, Ulrich Bogdahn, Peter Hau, Michael Fred Leitzmann |
| Abstract |
Statins have been reported to decrease the incidence of cancer, but the risk of glioma among statin users has been investigated in only two prior observational studies, both of them suggesting a modest protective effect of statins. We conducted a matched case-control study using data from the UK-based Clinical Practice Research Datalink to analyse use of statins among 2469 cases with glioma and 24,690 controls. We performed conditional logistic regression analysis to calculate relative risks, estimated as odds ratios (ORs) with 95 % confidence intervals (CIs) adjusting for multiple confounding factors. As compared with non-use of statins, use of statins was not associated with risk of glioma (OR for ≥90 prescriptions=0.75; 95 % CI 0.48-1.17). Our findings do not support previous sparse evidence of a possible inverse association between statin use and glioma risk. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 3% |
| Unknown | 31 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 25% |
| Researcher | 6 | 19% |
| Student > Master | 3 | 9% |
| Lecturer | 2 | 6% |
| Other | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 8 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 28% |
| Biochemistry, Genetics and Molecular Biology | 3 | 9% |
| Agricultural and Biological Sciences | 3 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Mathematics | 1 | 3% |
| Other | 4 | 13% |
| Unknown | 10 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2017.
All research outputs
#3,205,547
of 22,860,626 outputs
Outputs from European Journal of Epidemiology
#425
of 1,629 outputs
Outputs of similar age
#54,330
of 300,360 outputs
Outputs of similar age from European Journal of Epidemiology
#10
of 27 outputs
Altmetric has tracked 22,860,626 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,629 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 39.3. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,360 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.